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Abstract
Introduction: Glutaminase inhibitors target cancer cells by blocking the conversion of glutamine to glutamate,
thereby potentially interfering with anaplerosis and synthesis of amino acids and glutathione. The drug CB-839 has
shown promising effects in preclinical experiments and is currently undergoing clinical trials in several human
malignancies, including triple-negative breast cancer (TNBC). However, response to glutaminase inhibitors is variable
and there is a need for identification of predictive response biomarkers. The aim of this study was to determine
how glutamine is utilized in two patient-derived xenograft (PDX) models of breast cancer representing luminal-like/
ER+ (MAS98.06) and basal-like/triple-negative (MAS98.12) breast cancer and to explore the metabolic effects of CB-
839 treatment.
Experimental: MAS98.06 and MAS98.12 PDX mice received CB-839 (200 mg/kg) or drug vehicle two times daily p.o.
for up to 28 days (n = 5 per group), and the effect on tumor growth was evaluated. Expression of 60 genes and
seven glutaminolysis key enzymes were determined using gene expression microarray analysis and
immunohistochemistry (IHC), respectively, in untreated tumors. Uptake and conversion of glutamine were
determined in the PDX models using HR MAS MRS after i.v. infusion of [5-13C] glutamine when the models had
received CB-839 (200 mg/kg) or vehicle for 2 days (n = 5 per group).
Results: Tumor growth measurements showed that CB-839 significantly inhibited tumor growth in MAS98.06
tumors, but not in MAS98.12 tumors. Gene expression and IHC analysis indicated a higher proline synthesis from
glutamine in untreated MAS98.06 tumors. This was confirmed by HR MAS MRS of untreated tumors demonstrating
that MAS98.06 used glutamine to produce proline, glutamate, and alanine, and MAS98.12 to produce glutamate
and lactate. In both models, treatment with CB-839 resulted in accumulation of glutamine. In addition, CB-839
caused depletion of alanine, proline, and glutamate ([1-13C] glutamate) in the MAS98.06 model.
Conclusion: Our findings indicate that TNBCs may not be universally sensitive to glutaminase inhibitors. The major
difference in the metabolic fate of glutamine between responding MAS98.06 xenografts and non-responding
MAS98.12 xenografts is the utilization of glutamine for production of proline. We therefore suggest that addiction
to proline synthesis from glutamine is associated with response to CB-839 in breast cancer.
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Introduction
Alterations of metabolic pathways are a cancer hallmark,
resulting in dependencies on specific nutrients for cell
proliferation and tumor growth [1, 2]. In addition to glu-
cose, mammalian cells use glutamine to feed the tricarb-
oxylic acid (TCA) cycle as an alternative source of carbon,
and a precursor for proteins, lipids, and nucleic acids.
Glutamine is also a key precursor in the synthesis of the
antioxidant glutathione, which is important in maintaining
the redox balance in cells and tissues [3]. Furthermore,
glutamine can be converted via glutamate to proline,
which is found to play an important regulatory role in
cancer [4, 5]. Recent research has identified proline as an
important metabolite during adaption to hypoxia [6].
Although glutamine is a nonessential amino acid that
can be synthesized from glutamate, many cancer cells
depend on exogenous glutamine supply for proliferation
and tumor growth [7, 8]. Upregulated glutaminolysis is
observed in many aggressive forms of human cancer, in-
cluding colorectal cancer [9], gliomas [10], pancreatic
cancer [11], melanoma [12], and breast cancer [13, 14],
which highlights the importance of this amino acid in
tumor metabolism.
The rate-limiting step in glutamine metabolism is the
conversion of glutamine to glutamate, which is catalyzed
by the enzyme glutaminase [15]. Glutaminase exists in
several tissue-specific variants, encoded by two genes in
mammals, kidney-type glutaminase (GLS1), and liver-type
glutaminase (GLS2). GLS1 plays a central role in tumori-
genesis, whereas the role of GLS2 in cancer remains un-
clear. GLS1 has been found to be higher expressed in
TNBC compared to other subgroups of breast cancer [14]
and is essential for the survival of TNBC cells with a
deregulated glutaminolysis pathway [16].
Inhibition of glutaminase has been stated as an attract-
ive therapeutic approach in various cancers [8, 13, 14].
The glutaminase inhibitor CB-839 (Calithera) is cur-
rently being tested in clinical trials for several malignan-
cies including breast cancer (clinicaltrials.gov, ID:
NCT02071862). CB-839 is found to be specific to GLS1
and not to GLS2 [14]. Gross and colleagues found that
TNBC cell lines displayed a higher sensitivity to CB-839
compared to ER+ cell lines [14]. In addition, CB-839
caused a significant antitumor activity in two selected
xenograft models representing TNBC and basal-like/
HER2+ breast cancer. In a clinical phase I trial, two of
nine patients with TNBC treated with CB-839 experi-
enced stabilized disease [17]. While these studies have
shown promising results in the TNBC subgroup, there is
a need to identify better predictive response biomarkers
for optimal utilization and selection of patients that
more likely will respond to CB-839.
The overall aim of this study was to identify metabolic
characteristics associated with response to glutaminase
inhibitors in breast cancer. First, we showed that CB-839
treatment has a differential effect on the growth of two
patient-derived xenograft (PDX) models of breast cancer
representing luminal-like, ER+ (MAS98.06) and
basal-like, triple-negative (MAS98.12) breast cancer.
Then, we investigated the potential causes of this differ-
ential response by (i) assessing the expression of selected
genes and proteins directly involved in glutamine metab-
olism on tumor tissue from untreated mice and (ii)
measuring downstream glutamine metabolites in tumor
samples from CB-839-treated and untreated mice after
administration of [5-13C] glutamine using 13C
high-resolution magic angle spinning MR spectroscopy
(HR MAS MRS).
Materials and methods
Animal models
The MAS98.06 and MAS98.12 patient-derived breast
cancer xenograft models were established at the Institute
of Cancer Research, Oslo University Hospital, as previ-
ously described [18]. The models have previously been
classified as luminal B and basal-like molecular subtypes,
respectively [19]. MAS98.12 has a triple-negative pheno-
type, whereas MAS98.06 is estrogen- and
progesterone-receptor positive, and strongly dependent
on estradiol supplement for tumor growth [19, 20].
Tumor tissue was bilaterally and orthotopically trans-
planted into 5- to 6-week-old (18–20 g) female
Hsd:Athymic Nude-Foxn1nu mice. The animals were
kept under pathogen-free conditions at a temperature
between 19 and 22 °C, humidity between 50 and 60%, 20
air changes/h, and a 12-h light/dark cycle. The animals
were fed RM1 diet (Scanbur BK, Karlslunde, Denmark)
and distilled tap water ad libitum. The drinking water
was supplemented with 17-β-estradiol at a concentration
of 4 μg/ml in order to replicate the conditions described
in [18]. An overview of the experimental design is shown
in Additional file 1.
All procedures and experiments involving animals
were approved by the Norwegian Animal Research Au-
thority (FOTS ID: 7713 and 9126) and carried out ac-
cording to the European Convention for the Protection
of Vertebrates used for Scientific Purposes.
Tumor growth inhibition
Following bilateral transplantation, mice carrying MAS98.06
and MAS98.12 tumors (experiment 1) were kept until
tumor volume reached approximately 60mm3 (60.3mm3 ±
32.4mm3). Mice from both models were randomized to re-
ceive either CB-839 (200mg/kg) or drug-free vehicle two
times per day for up to 28 days (n = 5 per group). CB-839
(Calithera Biosciences, CA, USA) was dissolved in 10% cy-
clodextrin/saline solution and administered orally per gav-
age. Tumor length (l) and width (w) were measured using a
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digital caliper, and tumor volumes were calculated using the
formula V ¼ 16 ðπ l  w2Þ . The mice were sacrificed at
day 14 (MAS98.12) and day 28 (MAS98.06) when untreated
tumors approached the upper volume limit. Untreated tu-
mors were collected for histopathological examination and
HR MAS NMR (natural abundance) analysis.
Gene expression analysis
Gene expression analysis was performed (experiment 2)
using previously generated and published data [21].
Briefly, RNA was isolated from tumor tissue from six ani-
mals from each xenograft models and hybridized to 4 ×
44 k Agilent Whole Human Genome Oligo Microarrays
according to the manufacturer’s protocol. The microarray
data was normalized and analyzed using R(v 2.9.0) and the
LIMMA Bioconductor package [22], normalized and log2
transformed. The microarray data is accessible through
GEO Series accession number GSE37543. A total of 60
genes were selected for analysis, based on the KEGG maps
central carbon metabolism in cancer (map 05230), argin-
ine and proline biosynthesis (M00330), and glutathione
biosynthesis (M00118) [23], which outline potential meta-
bolic fates of glutamine in human cells.
Normalized and log2-transformed data was imported
into Qlucore Omics Explorer 3.3 (Qlucore AB, Lund,
Sweden) for statistical analysis. Testing for differential
expression of genes between the xenograft models was
performed using t tests with Empirical Bayesian correc-
tion of the test statistics [22]. To account for multiple
testing, an adjusted q value of 0.05 (using Benjamini &
Hochberg’s false discovery rate) was defined as the
threshold for statistical significance [24].
The heatmap was generated in R (v 3.3.2) using RStu-
dio (v 1.1.447). Hierarchical clustering was performed
using the in-house made R-package Clustermap [25]. In
brief, median-centered and log2-transformed RPPA data
were clustered using Euclidean distance and complete
linkage. For heatmap visualization of the data, values are
normalized to the range [− 1, 1] by application of a non-
linear sigmoid transformation f(x) = tanh(x). This limits
the visual dominance of outlier values while maintaining
the order of the values, since f is strictly increasing.
To determine whether the metabolic characteristics of
MAS98.06 and MAS98.12 xenografts are representative
of the luminal B and basal-like subtypes of breast cancer,
respectively, we accessed a previously published gene
expression data set that in total includes 19
basal-like and 7 luminal B PDX models [19]. Gene
expression of SLC1A5, GLS1, GLUL, and GLUD1
was accessed and are displayed as waterfall plots in
Additional file 2. The microarray data is available at
the Gene Expression Omnibus (GEO) with accession
number GSE44666.
Immunohistochemistry
IHC staining
Seven proteins (ALDH18A1, GLS1, GLUD1, GS, Myc,
PYCR1, SLC1A5) were selected for protein expression
analysis based on prior knowledge on their relevance in
glutaminolysis. Firstly, glutamine transporters ensure up-
take of glutamine into the cells, of which neutral amino
acid transporter B(0) (coded by the gene SLC1A5 (Solute
Carrier Family 1 Member 5), hereby abbreviated as
SLC1A5) has received high attention since it has been
shown that increased expression correlates with poor pa-
tient prognosis in many cancer types [9, 26–28]. Glu-
tamine synthetase (GS) is the enzyme that catalyzes the
conversion from glutamate to glutamine. Absence of GS
is correlated with high GLS1 activity and can be associ-
ated with glutamine addiction in invasive and aggressive
breast cancer phenotypes [29, 30]. Some cancer cells also
rely on glutamate dehydrogenase 1 (GLUD1)-mediated
Glu deamination to fuel the TCA cycle [31]. Glutamine
can be converted to proline via glutamate, and the en-
zymes pyrroline-5-carboxylate reductase 1 (PYCR1) and
aldehyde dehydrogenase 18 family member A1
(ALDH18A1) are found to be key enzymes in the con-
version [6, 32, 33]. The proto-oncogene Myc is shown to
be a key regulator of glutaminolysis affecting glutamine
uptake, GLS1 activity, and proline metabolism [4, 26,
34–36].
Tumors from untreated mice (experiment 1) were fixed
in 10% neutral-buffered formalin and embedded in paraf-
fin. Information about primary antibodies are presented in
a table in Additional file 3. GLUD1, SLC1A5, ALDH18A1,
and PYCR1 staining were performed at the Cellular &
Molecular Imaging Core Facility (CMIC), NTNU, Norway.
GLS1, GS, and cMYC staining were performed at Covance
Laboratories Inc., (Greenfield, USA). The following proto-
cols were applied: Tumor specimens were cut into 4 μm
sections which were dried, deparaffinized, and rehydrated.
Heat-induced antigen retrieval was then performed for 10
(Covance, Antigen Retrieval Solution, Leica, AR9661) or
20 (CMIC, Target Retrieval Solution: Dako, low pH 6,
K8005) minutes. Endogenous peroxidase activity was
quenched with peroxidase block (H2O2). Sections were in-
cubated with primary antibodies (Additional file 3) for 15
(Covance) or 40 (CMIC) mins in room temperature. Im-
munohistochemical reactions were visualized as specified
by the vendor using either (Covance) Dako Rabbit Envi-
sion+HRP with DAB+ for use with rabbit primary anti-
bodies (K4011, Dako) or (CMIC) Bond PDAB Reagent Kit
(Leica DS9800). Sections were counterstained with
hematoxylin.
IHC evaluation
Immunohistochemical markers were evaluated by a
semiquantitative approach used to assign the histo-score
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(H-score) for each tumor. The H-score is given as the
sum of the percentage of staining multiplied by an or-
dinal value corresponding to the intensity level (0 =
negative, 1 = weak, 2 = moderate, 3 = strong): [1 × (% cells
1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]. The final score,
ranging from 0 to 300, gives more relative weight to
higher intensity labeling in a given tumor sample [24,
37, 38].
An experienced pathologist from Covance Inc. scored
slides labeled with antibodies against GLS1, GS, and
cMYC. Two researchers (MTG and SAM) scored each
slide from GLUD1, SLC1A5, ALDH18A1, and PYCR1
independently in a blinded manner. Final H-score is
mean H-score ± SD from the two researchers. Some
MAS98.06 tumors had central necrosis, and areas with
necrosis were excluded from the analysis.
Glutamine metabolism
Another group of mice (experiment 3) carrying
MAS98.06 (n = 12, 30.0 ± 10.3 mm2) or MAS98.12 (n =
11, 41.4 ± 10.6 mm2) were randomly distributed to re-
ceive CB-839 or drug-free vehicle for 2 days as described
above. Three hours after the final treatment, animals re-
ceived an intravenous infusion of 13C-enriched glutam-
ine (99% enrichment, Cambridge Isotope Laboratories)
while under isoflurane anesthesia, as described in [39].
The mice received 1.2 mg [5-13C] glutamine/g body
weight, dissolved in sterile PBS. A 3-min bolus of 0.3
mg/g body weight was followed by continuous infusion
of 0.005 mg/g body weight/min for 180 min, in a total
infusion volume of 0.8 to 1.1 ml (depending on body
weight). The mice were sacrificed, and tumor tissue
samples were collected, snap frozen, and stored in liquid
nitrogen until NMR analysis.
NMR experiments
NMR spectroscopy of tumor tissue samples
Tumor samples from both 13C glutamine-labeled (n = 5
to six per group, experiment 3) and unlabelled (N.A.:
natural abundance, n = 3 per group, experiment 1) tu-
mors (39.9 ± 1.1 mg) were cut to fit into a 50-μl zirco-
nium HR MAS rotor (4-mm diameter). Lock reference
containing D2O with formate (25mM) was added to the
rotor (~ 16 μl). The HR MAS MR spectra were recorded
using a Bruker Advance DRX600 spectrometer (14.1 T)
(Bruker Biospin GmbH, Germany) containing a 1H/13C
MAS probe. Samples were spun at 5 kHz at magic angle,
and the temperature was kept at 4 °C during the whole ex-
periment. NMR spectra were acquired using the following
NMR sequences and acquisition parameters:
One-dimensional 1H NOESY pulse sequence with water
presaturation (Bruker; noesygppr1d). Acquisition time was
2.7 s, repetition time 6.7 s, sweep width was 30 ppm, and
128 scans were acquired. The 13C MR spectra were
acquired using a single pulse experiment, with 1H decoup-
ling applied during recycle delay and acquisition (Bruker;
zgpg30). The flip angle was 30°, acquisition time 0.9 s,
repetition time 1.9 s, sweep width 250 ppm, and 16 k scans
were obtained. Total acquisition time per sample was 9 h.
Analysis of NMR spectra
NMR spectra were Fourier transformed after application
of line broadening (1H: 0.3 Hz, 13C: 1 Hz for tumors),
and the chemical shift scale was calibrated to a reference
peak 1H: alanine at 1.48 ppm, 13C: [5-13C] glutamine
([5-13C] Gln) at 180.4 ppm.
For quantification of tumor metabolites from 1H NMR
spectra, ERETIC2 (Bruker), which is based on PULCON
(PULse length-based CONcentration determination),
was applied [40]. Each spectrum was scaled to sample
mass, and a total of four metabolites (alanine, glutamate,
glutamine, and lactate) were quantified (relative) using
Chenomx software (version 8.1, Alberta, Canada).
Tumor 13C NMR spectra were analyzed using MATLAB
R2017a (The Mathworks, Inc., USA). Baseline correction
was applied using an asymmetric least squares algorithm
[41], and the NMR spectra were scaled to NMR sample
mass. For determination of 13C-enriched peaks in tu-
mors, 20 relevant peaks from the 13C NMR spectra were
selected and integrated, and peaks that were significantly
higher (Student’s t test, p < 0.05) in [5-13C] labeled com-
pared to natural abundance tumors were considered 13C
enriched. The amount of eight 13C-labeled metabolites
in the tumors were calculated by subtracting natural
abundance spectra from 13C-enriched spectra. The re-
sults are shown in Additional file 4 (panel c).
The different experimental groups (13C-enriched con-
trols versus natural abundance controls from both models,
13C-enriched CB-839-treated versus 13C-enriched controls
from both models, and 13C-enriched MAS98.06 controls
versus 13C-enriched MAS98.12 controls) were compared
statistically using Student’s t test. P values less than 0.05
were considered statistically significant.
Results
CB-839 inhibits tumor growth in the luminal-like
(MAS98.06)
Tumor growth curves from CB-839-treated and untreated
MAS98.06 and MAS98.12 tumors (experiment 1) are dis-
played in Fig. 1 and show that CB-839 significantly inhib-
ited the growth rate in MAS98.06 tumors. In treated mice,
the tumor volume at day 28 was 28% of the volume of un-
treated controls (p = 0.0007). For the MAS98.12 model,
no significant growth inhibition was observed.
Expression of genes involved in glutaminolysis
In untreated tumors (experiment 2), we observed that
31 genes were significantly higher expressed in
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MAS98.06 than in MAS98.12 tumors, of which 12 had
at least a two-fold higher expression. For the MAS98.12
tumors, we observed that 17 genes were significantly
higher expressed in this model compared to MAS98.06
tumors, of which 11 had at least a two-fold higher ex-
pression. The expression of all genes, as well as a sche-
matic overview of genes that have at least a two-fold
different expression between the models is presented in
Fig. 2. A full overview of genes, expression levels and q
values is given as Additional file 5. Among the seven key
enzymes that were selected for IHC analysis, we ob-
served that the gene expression of GLUL and SLC1A5,
as well as the important genes responsible for conver-
sion between glutamate and proline, i.e., ALDH18A1 and
PYCR1, were significantly more highly expressed in the
responding MAS98.06 model. Contrarily, GLS1 and
MYC were significantly more highly expressed in
MAS98.12 tumors. Of note, SLC38A2 had two probes
and the expression from both are displayed in the figure
and table.
The expression of SLC1A5, GLS1, GS, and GLUD1
was compared across 19 basal-like and 7 luminal B PDX
models (Additional file 2). Within both basal-like and lu-
minal B models, a considerable variability (generally
five-fold to ten-fold difference) in the expression of these
key genes was observed.
Key proteins involved in glutaminolysis are differentially
expressed in the two models
For better understanding of the differences in glutamine
utilization between the models (experiment 1), we per-
formed immunohistochemical (IHC) analysis on selected
proteins involved in glutamine metabolism in untreated
tumors. Figure 3 shows percentage areas with different
DAB intensity for each antibody and model in addition
to representative images. Using H-score as an indicator
of protein expression in the two xenograft models,
MAS98.06 tumors had significantly higher expression of
the two important enzymes responsible for conversion
from glutamate to proline, i.e., ALDH18A1 (p < 1e−5),
and PYCR1 (p < 0.05) in addition to GLUD1 (p < 0.05).
They also had a significantly lower expression of
SLC1A5 (p < 0.001) compared to MAS98.12 tumors. All
H-scores are presented in Table 1. It was noted that
SLC1A5 expression was higher in peripheral than intra-
tumoral areas in MAS98.06 tumors, whereas MAS98.12
tumors were strongly stained throughout the tumor. A
similar pattern was found for GLUD1, where MAS98.06
tumors displayed strong staining in peripheral areas and
MAS98.12 tumors also displayed strong staining in
intratumoral areas close to stromal cells.
Untreated MAS98.06 and MAS98.12 tumors utilize [5-13C]
glutamine differently
To determine the consumption and metabolic fate of
glutamine in untreated xenografts, we performed in vivo
glutamine tracing experiments (experiment 3). Main
findings are shown in Fig. 4. Comparing the
glutamine-enriched samples with natural abundance
spectra (from experiment 1), we found that the xeno-
grafts take up significant amounts of glutamine. Both
models also use glutamine for anaplerotic fueling of the
TCA cycle. However, while MAS98.12 tumors seem to
rapidly metabolize glutamine into glutamate, lactate, and
alanine, MAS98.06 tumors accumulate significant
amounts of glutamine in the tumor tissue. Furthermore,
MAS98.06 tumors use glutamine for production of pro-
line, alanine, and lactate, in addition to glutamate and
glutamine after one turn in the TCA cycle ([1-13C] Glu
and [1-13C] Gln). A detailed presentation of 13C NMR
spectra, in addition to 13C enriched and 1H metabolites
for each group, are shown in Additional file 4. Of note,
the tumor sample from one mouse with MAS98.12
xenograft had a significantly outlying 13C NMR
spectrum, characterized with significantly higher
amounts of [5-13C] Gln compared to the other samples
in the same experimental group (Dixon’s Q test for out-
liers performed on the amount of [5-13C]-Glu in un-
treated MAS98.12 tumors showed Qexp = 0.80 >
Fig. 1 Effect of CB-839 on tumor growth in luminal-like (MAS98.06) and basal-like (MAS98.12) PDX models. CB-839 significantly (p < 0.001) reduces
tumor growth in MAS98.06 tumors. Tumor growth of MAS98.12 breast cancer xenografts is not affected by CB-839. Mean ± SEM values are
plotted. N = 5 for each group
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QcritCL95% = 0.71) [42, 43]. The samples from this mouse
were removed from the results.
CB-839 causes depletion of Pro, Ala, and Glu in the
MAS98.06 model
To identify the effect of CB-839 treatment on MAS98.06
and MAS98.12 tumors, we also analyzed 13C NMR spectra
from CB-839-treated tumors following infusion with
13C-labeled glutamine ([5-13C] Gln). Main findings from
the 13C NMR data from treated models are shown in Fig. 5.
Figure 5a shows mean 13C NMR spectra along with
amounts of selected 13C-enriched metabolites (Fig. 5b) in
each experimental group. A schematic overview of the
most important effects of CB-839 is shown in Fig. 5c, illus-
trating how CB-839 caused accumulation of [5-13C] Gln in
both tumor models, without affecting the [5-13C] Glu
levels. In addition, it shows that CB-839 caused depletion
of the downstream metabolites [5-13C] Pro and [1-13C] Ala
(See figure on previous page.)
Fig. 2 Expression of genes involved in glutaminolysis from untreated MAS98.06 and MAS98.12 tumors. a Heatmap of expression of the 60 selected
genes involved in glutaminolysis in untreated MAS98.06 and MAS98.12 tumors. b Differences in gene expression between untreated MAS98.06 and
MAS98.12 xenografts. Blue, the gene is significantly higher expressed with at least a two-fold higher expression in MAS98.06; red, the gene is
significantly higher expressed with at least two-fold higher expression in MAS98.12; white, the gene is not significantly different expressed between
the models. Log2-fold change (log2FC) between the two models is indicated by color intensity. Dotted arrows from Myc indicate some of the most
important genes that are positively (+) and negatively (−) regulated by Myc, as shown by others [4, 26, 34–36]. Full gene names, enzyme commission
numbers (EC numbers), gene expression levels, q values, log2 fold change, and fold changes are specified in Additional file 5
Fig. 3 H-scores and representative images from IHC of untreated MAS98.06 and MAS98.12 tumors. The tumors were stained with antibodies
against aldehyde dehydrogenase 18 family member A1 (ALDH18A1), cMYC, glutamate dehydrogenase 1 (GLUD1), glutaminase (GLS1), glutamine
synthetase (GS), pyrroline-5-carboxylate reductase 1 (PYCR1), and solute carrier family 1 member 5 (SLC1A5). Left columns present the percentage
areas with different intensity levels (DAB: 3′-diaminobenzidine) for MAS98.06 (blue shades), and MAS98.12 (red shades) tumors. Neg, no labeling; 1
+, light label; 2+, moderate label; 3+, dark label. Right columns show representative IHC images for each antibody for both MAS98.06 tumors
(left) and MAS98.12 tumors (right) in two different magnifications of × 4 and × 20. Scale bar is 200 μm for × 4 magnification and 50 μm for × 20
magnification. *p < 0.05, ***p < 0.001, *****p < 0.00001
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in MAS98.06 tumors. Box plots of the amount of all
13C-enriched metabolites and relevant 1H metabolites for
all experimental groups are shown in Additional file 6.
Discussion
In this study, we have evaluated the treatment response
to the glutaminase inhibitor CB-839 in two breast cancer
PDX models. Previous studies suggest that basal-like and
triple-negative breast cancers are more sensitive to glu-
taminase inhibitors than luminal-like and ER+ sub-
groups [14, 16]. Our findings complement this
paradigm; The MAS98.06 xenografts, previously found
to belong to the luminal B subtype, were sensitive to
glutaminase inhibition whereas the basal-like MAS98.12
xenografts did not respond to treatment.
Previous reports have suggested that TNBC and
basal-like breast cancer are particularly dependent on
glutamine for proliferation and tumor growth [14, 16,
44]. Gross and colleagues showed that the TNBC sub-
type displayed the greatest sensitivity to CB-839 treat-
ment in vitro and that the sensitivity was positively
correlated to dependence on extracellular glutamine for
growth, high baseline ratio of intracellular glutamate to
glutamine (Glu:Gln), and expression of glutaminase
(GLS1) [14]. A high Glu:Gln ratio has been proposed as
an independent diagnostic entity. Although other studies
indicate significant differences in Glu:Gln between breast
cancer subgroups, a high Glu:Gln phenotype is observed
across all the molecular subtypes [45]. In our experi-
ments, we observed that the triple-negative/basal-like
MAS98.12 model had significantly higher gene expres-
sion of GLS1 and a trend of higher GLS1 protein
Table 1 Histo-scores (H-score, mean ± stdev) and p values from
selected antibodies
Protein Histo-score Level of significance
MAS98.06 MAS98.12 p value
ALDH18A1 147 ± 25 23 ± 9 6e−06
cMYC 99 ± 52 159 ± 32 ns (0.06)
GLUD1 131 ± 35 86 ± 11 0.03
GLS1 210 ± 25 256 ± 43 ns (0.08)
GS 164 ± 25 168 ± 38 ns (0.85)
PYCR1 128 ± 24 90 ± 18 0.02
SLC1A5 132 ± 17 178 ± 6 4e−04
Abbreviations: ALDH18A1 aldehyde dehydrogenase 18 family member A1,
GLUD1 glutamate dehydrogenase 1, GLS1 glutaminase, GS glutamine
synthetase, ns not significant, PYCR1 pyrroline-5-carboxylate reductase 1, and
SLC1A5 solute carrier family 1 member 5 (glutamine transporter)
a b
Fig. 4 Utilization of [5-13C] Gln in untreated luminal-like (MAS98.06) and basal-like (MAS98.12) tumor xenografts. a 13C labeling patterns in
MAS98.06 and MAS98.12 tumors after administration of [5-13C] Gln. MAS98.06 tumors (blue) use [5-13C] Gln to produce [5-13C] Glu, [5-13C] Pro,
[1-13C] Ala, [1-13C] Glu, and [1-13C] Lac (gray, only borderline significant). They also store a significant amount of [5-13C] Gln in the tumors.
MAS98.12 tumors (pink) take up [5-13C] Gln and use it for production of [5-13C] Glu, [1-13C] Lac and [5-13C] Ala (gray, only borderline significant). b
Amount of 13C-labeled metabolites in the tumors, calculated by subtracting natural abundance spectra from 13C-enriched spectra. Stars (*)
indicate that there is a significantly higher amount of the metabolite in 13C-enriched samples compared to natural abundance samples, while up
arrowheads (^) indicate borderline significance. The total amount of 13C-labeled metabolites were not significantly different between the two
models. ^p < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: Ala, alanine; Gln, glutamine; GLS1, glutaminase; Glu, glutamate; Lac, lactate; Pro,
proline; Pyr, pyruvate; TCA, tricarboxylic acid
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expression, and a significantly higher Glu:Gln ratio com-
pared to the luminal B/ER+ MAS98.06 models. Despite
the accordance with previously proposed predictive bio-
markers, the MAS98.12 model did not respond to
CB-839 treatment, suggesting that response and resist-
ance depend on other mechanisms regulating glutamine
metabolism. Metabolic redundancy or plasticity can res-
cue cancer cells from glutaminase inhibition, and our
understanding of metabolic characteristics within the
molecular breast cancer subtypes remains limited. Sev-
eral studies have demonstrated metabolic variability
within subtypes and a lack of correlation between meta-
bolic and transcriptomic traits [46, 47]. Although the
triple-negative phenotype has been suggested to be par-
ticularly dependent on glutaminolysis, it has been shown
that as many as 25% of these do not express GLS1 as de-
termined by immunohistochemistry [48]. In a panel of
26 PDX models, we found more than ten-fold difference
in the expression of GLS1 within the basal-like subtype
(Additional file 2). Similar variability was observed for
SLC1A5, GS, and GLUD1. Both MAS98.06 and
MAS98.12 displayed GLS1 expression higher than the
average for the cohort. No clear distinctions between
basal-like and luminal B xenografts were observed for
any of the genes. This indicates that although the two
subtypes display metabolic differences on the population
level, it must be expected that individuals within each
subtype display atypical metabolic characteristics.
In order to better understand mechanisms responsible
for response and resistance to glutaminase inhibitors, we
studied glutamine utilization in the two xenografts by in-
fusion of 13C-enriched glutamine and ex vivo 13C NMR
tumor analysis, combined with gene- and protein ex-
pression data. From the 13C HR MAS MRS analysis on
untreated models, we saw that the two xenograft models
utilize glutamine differently. Although the total glutam-
ine consumption was similar in the two models, the
main metabolic fate of glutamine in the non-responding
a
b c
Fig. 5 Effect of CB-839 on glutamine metabolism in MAS98.06 and MAS98.12 PDX tumors. a Average 13C NMR spectra (173.5-185.5 ppm and 75-
13 ppm) for CB-839-treated and untreated MAS98.06 (blue) and MAS98.12 (red) tumors receiving 13C-labeled glutamine. The contribution to the
average from each individual NMR spectrum is scaled to the sample mass. b Quantified amounts of selected 13C-labeled metabolites in each
experimental group: 13C glutamine ([5-13C] Gln), glutamate to glutamine ratio ([5-13C] Glu/[5-13C] Gln), alanine ([1-13C] Ala), and proline ([5-13C]
Pro) in the experimental groups. c MAS98.06 tumors take up and store glutamine (Gln) and use glutamine to produce glutamate (Glu), proline
(Pro), alanine (Ala), lactate (Lac), and glutamate (Glu) through one turn in TCA cycle, as indicated by the filled blue circles (gray circle for Lac, only
borderline significant). CB-839 causes an accumulation of Gln (arrow up) and reduced amounts of Pro, Al, and Glu (arrows down) in the tumors
(only [1-13C] Glu, which is created after one turn in TCA cycle, is reduced). MAS98.12 tumors use glutamine (Gln) to produce Glu, Lac, and Ala as
indicated by filled pink circles (gray circle for Ala, only borderline significant). CB-839 causes accumulation of Gln in MAS98.12 tumors, but does
not significantly change the amount of any other 13C-enriched metabolites *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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MAS98.12 was conversion into glutamate, lactate, and
alanine. In contrast, the responding MAS98.06 tumors
store significant amounts of glutamine in the tumors,
but also use glutamine for synthesis of proline, alanine,
and lactate. Both models use a similar fraction of the
glutamine to feed the TCA cycle, as seen by the presence
of [1-13C] glutamate (MAS98.06) and [1-13C] lactate
(MAS98.12).
A possible scenario that may explain why some tumors
are insensitive to CB-839 is that they use glycolysis in-
stead of glutaminolysis for anaplerotic feeding of the
TCA cycle. Pyruvate can enter the TCA cycle through
dehydrogenation of pyruvate into acetyl-CoA (which is
catalyzed by pyruvate dehydrogenase (PDH)) or through
carboxylation of pyruvate into oxaloacetate (catalyzed by
pyruvate carboxylase (PC)). However, we have previously
found that following [1-13C] Glc injection, MAS98.12 tu-
mors feed less glucose into the TCA cycle than
MAS98.06 tumors, both via PDH and PC [49]. Differ-
ences in anaplerotic fueling of the TCA by glucose can
therefore not explain the differences in response to
CB-839 observed in this study.
It is well established that the signaling landscape plays
critical roles in regulating proliferation and tumor
growth [50]. The transcription factor Myc affects glu-
tamine metabolism by enhancing glutamine uptake, glu-
taminase activity, and upregulation of proline
metabolism [4, 26, 34–36]. Myc may trigger addiction to
glutamine, which is observed both in vitro and in vivo
[8, 50]. Several transporters are capable of transporting
glutamine across the plasma membrane [26]. Among
these, SLC1A5 has received increased attention because
its expression is upregulated in many cancer types, in-
cluding triple-negative breast cancer [27]. We observed
that MAS98.12 xenografts display a borderline signifi-
cant higher expression of MYC than MAS98.06 xeno-
grafts. This may explain the higher expression of the
glutamine transporter SLC1A5 protein and GLS1 mRNA
in MAS98.12. However, expression of MYC was not as-
sociated with increased glutamine consumption or pro-
line synthesis in our models.
In tumor tissue from the responding MAS98.06
model, we saw a depletion of proline and alanine after
treatment. Alanine is produced from pyruvate, which
can be synthesized using several routes, including gly-
colysis. Proline, on the other hand, is a conditionally es-
sential amino acid [51]. In untreated MAS98.06
xenografts, a significant fraction of the injected [5-13C]
glutamine was converted to [5-13C] proline. This is con-
sistent with gene and protein expression data, showing
that ALDH18A1 and PYCR1 were more highly
expressed in MAS98.06 than MAS98.12 both on gene
and protein expression level. These results indicate that
MAS98.06 tumors have a higher flux from glutamate to
proline compared to MAS98.12 tumors. Recent research
by Tang and colleagues has identified proline as an im-
portant metabolite in cancer, linked to adaption to
tumor hypoxia [6]. They showed that hypoxic microen-
vironments activated proline metabolism via upregula-
tion of ALDH18A1 in tumor samples from patients with
hepatocellular carcinoma. We have previously shown
that the luminal-like MAS98.06 tumors are more hyp-
oxic than basal-like MAS98.12 tumors [20]. It could
therefore be speculated that MAS98.06 tumors adapt to
hypoxic microenvironments through activation of
proline-mediated mechanisms. Depletion of proline fol-
lowing CB-839 treatment to the MAS98.06 models
could leave the tumors unable to handle hypoxic stress,
consequently inhibiting the growth of these tumors.
Overall, our results indicate that current biomarkers
suggested for predicting response to glutaminase inhib-
ition do not fully capture the complexity of glutamine me-
tabolism in cancer and that the response to glutaminase
inhibitors depends on the individual tumor’s ability to
compensate for reduced glutamate availability. One pos-
sible explanation for the glutamine dependence in
MAS98.06 tumors is that they use glutamine in proline
biosynthesis, for adaption to hypoxic microenvironments.
Conclusion
This work demonstrates that the glutaminase inhibitor
CB-839, which currently is in early clinical trials for
TNBC patients, significantly inhibits tumor growth in
one of the breast cancer PDX models, the luminal b/ER
+ MAS98.06 model. However, it had no effect on tumor
growth in the other basal-like/triple-negative MAS98.12
PDX model. Gene expression analysis and IHC show
that the responding model (MAS98.06) has higher gene
and protein expressions of enzymes involved in the con-
version of glutamine to proline. 13C NMR data of tissue
from untreated tumors supports these findings, as the
responding model has higher proline synthesis than the
non-responding model. Following treatment with
CB-839, 13C NMR demonstrated proline depletion in
the responding model. One possible explanation is that
the responding MAS98.06 model, which is found to be
more hypoxic than non-responding MAS98.12, is
dependent on proline synthesis from glutamine to adapt
to the hypoxic microenvironment. Our study illustrates
the shortcomings of currently proposed predictive bio-
markers of response to glutaminase inhibition in breast
cancer.
Additional files
Additional file 1: Figure with an overview of the PDX models and
experimental design of the study. Abbreviations: HR MAS MRS, high-
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resolution magic angle spinning MR spectroscopy; IHC, immunohisto-
chemistry; N.A., natural abundance (PPTX 359 kb)
Additional file 2: Figure with gene expression of SLC1A5, GLS1, GLUL,
and GLUD1 in 19 basal-like and 7 luminal B PDX models. The gene ex-
pression data of SLC1A5, GLS1, GLUL, and GLUD1 in 19 basal-like PDX tu-
mors (red) and 7 basal-like PDX tumors (cyan) is presented in waterfall
plots. The expressions for each genes are mean normalized. The micro-
array data are collected from the Gene Expression Omnibus (GEO) with
accession number GSE44666 (PPTX 31009 kb)
Additional file 3: Table with overview of primary antibodies. Gives
information about species reactivity, suppliers and product information,
host species, and antibody dilution used during immunohistochemistry
(IHC) staining (DOCX 13 kb)
Additional file 4: Figure showing HR MAS MRS data from untreated
MAS98.06 and MAS98.12 tumors. a) Average 13C HR MAS MRS spectra
calculated by subtracting natural abundance spectra from 13C enriched
spectra. Positive signals with stars (*) indicate that there is a significantly higher
amount of the metabolite in 13C-enriched samples compared to natural
abundance samples, whereas up arrowheads (^) indicate borderline
significance. b) Amount of 13C-labeled metabolites in the tumors, calculated
by subtracting natural abundance spectra from 13C-enriched spectra. Stars (*)
indicate that there is a significantly higher amount of the metabolite in 13C-
enriched samples compared to natural abundance samples, and up
arrowheads (^) indicate borderline significance. The total amount of 13C-
labeled metabolites were not significantly different between the two models.
c) Box plots showing the amount of the 13C-labeled metabolites subtracted
with the amount of the metabolites from the natural abundance spectra. d)
Amounts of selected metabolites from 1H spectra calculated from natural
abundance and 13C-enriched samples. *p< 0.05, **p < 0.01, ***p< 0.001.
Abbreviations: Ala, alanine; Gln, glutamine; GLS,: glutaminase; Glu, glutamate;
Lac, lactate; Pro, proline; Pyr, pyruvate; TCA, tricarboxylic acid (PPTX 1939 kb)
Additional file 5: Table with gene expression data from the 60 selected
genes. The table gives information about gene symbols, probe names,
the associated EC number, p values and q values, gene expression levels
for both models (log2 transformed), log2 fold change, and fold change.
The table includes the same color coding system as Fig. 2 in the article.
The seven selected key genes are marked in bold (DOCX 23 kb)
Additional file 6: Figure showing the effect of CB-839 in MAS98.06 and
MAS98.12 tumors. a) Average 13C NMR spectra (173.5-185.5 ppm and 75-
13 ppm) for CB-839-treated and untreated MAS98.06 and MAS98.12
models receiving 13C-labeled glutamine. b) Quantified amounts of 13C-la-
beled metabolites in each experimental group: 13C glutamine ([5-13C]
Gln), glutamate ([5-13C] Glu and [1-13C] Glu), alanine ([1-13C] Ala), lactate
([1-13C] Lac, proline ([5-13C] Pro), and glutamate to glutamine ratio
([5-13C] Glu/[5-13C] Gln) in the experimental groups. c) MAS98.06 tumors
take up and store glutamine (Gln) in the tumors and use glutamine to
produce proline (Pro), alanine (Ala), lactate (Lac), and glutamate (Glu)
through one turn in TCA cycle as indicated by filled blue circles (Lac only
borderline significant, gray circle). CB-839 causes an accumulation of Gln
(arrow up) and reduced amounts of Pro, Ala, and Glu (arrows down) in
the tumors (only [1-13C] Glu, which is created after one turn in TCA cycle,
is reduced). MAS98.12 tumors use glutamine (Gln) to produce Glu, Lac,
and Ala as indicated by filled pink circles (Ala only borderline significant,
gray circle). CB-839 causes accumulation of Gln in MAS98.12 tumors, but
does not significantly change the amount of any other 13C-enriched me-
tabolites. d) Quantified amount of relevant metabolites from 1H spectra.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (PPTX 339 kb)
Abbreviations
Ala: Alanine; ALDH18A1: Aldehyde dehydrogenase 18 family member A1;
DAB: 3,3′-Diaminobenzidine; ER+: Estrogen receptor positive; Gln: Glutamine;
GLS1/GLS2: Glutaminase 1/glutaminase 2; Glu: Glutamate; GLUD1: Glutamate
dehydrogenase 1; GLUL: Glutamine synthetase (gene); GS: Glutamine
synthetase (protein); HR MAS MRS: High-resolution magic angle spinning MR
spectroscopy; HRP: Horseradish peroxidase; Lac: Lactate; NMR: Nuclear
magnetic resonance; PDH: Pyruvate dehydrogenase; PDX: Patient-derived
xenograft; Pro: Proline; PYCR1: Pyrroline-5-carboxylate reductase 1;
SLC1A5: Solute carrier family 1 member 5; SLC38A2: Solute carrier family 38
member 2; TNBC: Triple-negative breast cancer
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